It’s been a transformative year for synthetic biology and for the world. The COVID-19 pandemic exposed weaknesses in our global health systems but also validated the power of synthetic biology to rapidly develop critical diagnostics and mRNA vaccines. I spoke with Rahul Dhanda, CEO of Sherlock Biosciences, one of the leading Crispr diagnostics companies. 

Today, Sherlock announced a new partnership with LogicInk  to leverage Sherlock’s Crispr platform to develop a wearable COVID-19 test. What is synthetic biology’s role in the next stages of the pandemic and what could the next 12 months look like for the industry and for Crispr-based diagnostics?